Navigation Links
Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced three abstracts accepted for poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and the clinical trial of DN24-02 in bladder cancer at the upcoming American Society for Clinical Oncology annual meeting in Chicago, Illinois.

The three abstracts will be presented on Monday, June 6, 2011, from 8:00 a.m. to 12:00 p.m. CT in the McCormick Place Hall A at the American Society for Clinical Oncology Annual Meeting.

  • Abstract TPS188:  Planned Phase 3 trial – called ACTION – in metastatic, androgen-dependent prostate cancer will compare subjects who receive androgen deprivation therapy (ADT) only with subjects who receive ADT and PROVENGE. The global, randomized, open-label trial will measure overall survival in a targeted enrollment of 1,684 patients, with additional endpoints that include safety, castrate resistant-free survival, chemotherapy-free survival, and quality of life.  
  • Abstract TPS189:  Planned Phase 2 study examining the effects of using PROVENGE before or after androgen deprivation therapy in men with a rising PSA following primary therapy for prostate cancer. The study is targeted to enroll 60 patients and is designed to assess the impact of the two approaches on immune markers.
  • Abstract TPS187:  Phase 2 study of DN24-02 – called Neu-ACT – in patients with surgically resected urothelial cancer, including bladder cancer, who are at a high risk of recurrence. Up to 180 patients will be randomized to receive either standard of care or DN24-02, an active cellular immunotherapy product candidate targeting HER 2/neu that is based on the same platform as PROVENGE. Endpoints include overall survival, disease-free survival, and immune response.'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of PROVENGE Data at the 2011 American Society of Clinical Oncology Annual Meeting
2. Dendreon Announces Presentation of Data at the American Association of Cancer Research Annual Meeting
3. Dendreon Announces Webcast Presentations at Upcoming Conferences
4. Dendreon Expands Launch of PROVENGE
5. Dendreon Announces Exercise and Closing of Overallotment Option
6. Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016
7. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
8. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
9. Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
10. Dendreon Reports Third Quarter 2010 Financial Results
11. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... HERZLIYA PITUACH, Israel , Dec. 15, 2014 ... IMNP ) announced today that its Board of Directors has ... Daniel Teper who continues as Chief Executive Officer ... Board of Directors since 2013. Immune,s new Chairman, ... represent the interest of shareholders and to continue to support ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ), ... small molecule drugs for the treatment of cancer and ... host a conference call and live audio webcast on ... the company,s second quarter fiscal 2011 financial and operational ...
... Health today announced that its board of directors has approved a ... to shareholders of record on April 1. This marks the 106th ... Cardinal Health Headquartered in Dublin, Ohio, Cardinal ... health care services company that improves the cost-effectiveness of ...
Cached Medicine Technology:Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011 2Cardinal Health Declares Regular Quarterly Dividend 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... including having a discussion at home about how to prevent ... household, according to a study of the initial outbreak in ... issue of The Journal of Infectious Diseases , the ... influenza symptoms are often told to stay home from work ...
... parents of children with multiple medical problems, keeping up with ... can be overwhelming, especially for those in challenging socioeconomic situations. ... up using the emergency room, the country,s most expensive form ... But a growing concept in health care reform ...
... Reflecting the changing economic landscape, more older workers are staying in the work force, but increasingly in part-time rather than full-time jobs, according to new research released today ... ... ... ...
... survival doubled after the treatment, study found , TUESDAY, ... powerful regimen of radiation therapy kept early-stage lung tumors ... 56 percent of patients who underwent the therapy, called ... years after their treatment, according to preliminary findings from ...
... Highly-focused stereotactic body radiation therapy (SBRT) can ... and may ultimately improve survival for patients with ... findings of a Radiation Therapy Oncology Group study ... the Journal of the American Medical Association ...
... Carnegie Mellon University will host "Invention to Venture," a ... students interested in learning about what it takes to ... a wide range of topics including entrepreneurship, intellectual property ... assistant professor of engineering and public policy at Carnegie ...
Cached Medicine News:Health News:Preventive behaviors limited household transmission of H1N1 influenza during initial outbreak 2Health News:Preventive behaviors limited household transmission of H1N1 influenza during initial outbreak 3Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 2Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 3Health News:New Research from EBRI: Older Workers Trending Toward More Part-Time Work 2Health News:New Research from EBRI: Older Workers Trending Toward More Part-Time Work 3Health News:Radiation May Help Those With Inoperable Lung Tumors 2Health News:Radiation May Help Those With Inoperable Lung Tumors 3Health News:SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients 2Health News:SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients 3
... growth factor I (IGF-I or somatomedin C) is ... liver. It acts as a potent mitogen of ... specific cell-surface receptors. In the circulation, IGF-I is ... regulate the actions of IGF-I by modulating the ...
... potent naturally occurring androgen produced from ... 5a-reductase [1]. The concentrations of ... tissues, including genital skin and hair ... apparent association with the nuclear membrane. ...
Urovac bladder evacuator with adaptor...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Medicine Products: